A Texas judge has finalized a $158 million settlement between Texas and a subsidiary of health care giant Johnson & Johnson in a Medicaid fraud lawsuit over the anti-psychotic drug Risperdal.
The agreement, reached during a January trial settled a lawsuit that accused J&J and its subsidiaries of fraud by false or misleading statements about the safety, cost and effectiveness of the drug.
The settlement was approved during a court hearing Tuesday in Austin.
The whistleblower lawsuit was filed by Allen Jones. His attorney, Tom Melsheimer, said Texas will get 40 percent of the settlement; the federal government gets 31 percent; Jones gets 17 percent; and 12 percent goes to attorneys’ fees.
The health care giant has said it’s not admitting fault with the settlement.
Was this article valuable?
Here are more articles you may enjoy.
Portugal Rolls Out $2.9 Billion Aid as Deadly Flooding Spreads 
LA County Told to Pause $4B in Abuse Payouts as DA Probes Fraud Claims 
One out of 10 Cars Sold in Europe Is Now Made by a Chinese Brand 
Berkshire Utility Presses Wildfire Appeal With Billions at Stake 
Want to stay up to date?
Get the latest insurance news
sent straight to your inbox.